首页|Molecular features of gastroenteropancreatic neuroendocrine carcinoma:A comparative analysis with lung neuroendocrine carcinoma and digestive adenocarcinomas

Molecular features of gastroenteropancreatic neuroendocrine carcinoma:A comparative analysis with lung neuroendocrine carcinoma and digestive adenocarcinomas

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
Objective:There is an ongoing debate about whether the management of gastroenteropancreatic(GEP)neuroendocrine carcinoma(NEC)should follow the guidelines of small-cell lung cancer(SCLC).We aim to identify the genetic differences of GEPNEC and its counterpart.Methods:We recruited GEPNEC patients as the main cohort,with lung NEC and digestive adenocarcinomas as comparative cohorts.All patients undergone next-generation sequencing(NGS).Different gene alterations were compared and analyzed between GEPNEC and lung NEC(LNEC),GEPNEC and adenocarcinoma to yield the remarkable genes.Results:We recruited 257 patients,including 99 GEPNEC,57 LNEC,and 101 digestive adenocarcinomas.Among the mutations,KRAS,RB1,TERT,IL7R,and CTNNB1 were found to have different gene alterations between GEPNEC and LNEC samples.Specific genes for each site were revealed:gastric NEC(TERT amplification),colorectal NEC(KRAS mutation),and bile tract NEC(ARID1A mutation).The gene disparities between small-cell NEC(SCNEC)and large-cell NEC(LCNEC)were KEAP1 and CDH1.Digestive adenocarcinoma was also compared with GEPNEC and suggested RB1,APC,and KRAS as significant genes.The TP53/RB1 mutation pattern was associated with first-line effectiveness.Putative targetable genes and biomarkers in GEPNEC were identified in 22.2％of the patients,and they had longer progression-free survival(PFS)upon targetable treatment[12.5 months vs.3.0 months,HR=0.40(0.21-0.75),P=0.006].Conclusions:This work demonstrated striking gene distinctions in GEPNEC compared with LNEC and adenocarcinoma and their clinical utility.

Neuroendocrine carcinomagastroenteropancreaticlunggenetic alterationsmolecular markers

Jianwei Zhang、Hanxiao Chen、Junli Zhang、Sha Wang、Yanfang Guan、Wenguang Gu、Jie Li、Xiaotian Zhang、Jian Li、Xicheng Wang、Zhihao Lu、Jun Zhou、Zhi Peng、Yu Sun、Yang Shao、Lin Shen、Minglei Zhuo、Ming Lu

展开 >

Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Gastrointestinal Oncology,Peking University Cancer Hospital & Institute,Beijing 100142,China

Department of Radiation Therapy,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Shenzhen 518172,China

Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department Ⅰ of Thoracic Oncology,Peking University Cancer Hospital & Institute,Beijing 100142,China

Medical Department,Nanjing Geneseeq Technology Inc.,Nanjing 210061,China

Geneplus-Beijing,Beijing 102200,China

State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers,Beijing Key Laboratory of Carcinogenesis and Translational Research,Department of Gastrointestinal Oncology,Peking University Cancer Hospital & Institute,Beijing 100142,China

Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Pathology,Peking University Cancer Hospital & Institute,Beijing 100142,China

展开 >

Major Program of National Natural Science Foundation of ChinaNational Natural Science Foundation of ChinaCapital's Funds for Health Improvement and Research(CFH)Beijing Xisike Clinical Oncology Research Foundation Y-pierrefabreBeijing Municipal Administration of Hospitals Incubating ProgramScience Foundation of Peking University Cancer Hospital

91959205821411172022-2-1023202101-0099PX20200452020-4

2024

10.21147/j.issn.1000-9604.2024.01.09

中国癌症研究(英文版)
中国抗癌协会 北京市肿瘤研究所

中国癌症研究(英文版)

CSTPCD
影响因子：1.592
ISSN：1000-9604
年,卷(期)：2024.36(1)
  • 53